Pacira Regenerative Medicine Advance Therapy (RMAT) Designation for Knee Osteoarthritis

 PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis --

-- Designation supported by encouraging preliminary data from 72-patient Phase 1 study --

-- 52-Week Data Accepted for Presentation at OARSI 2024 and 104-week data to be submitted for presentation later this year --

https://www.biospace.com/article/releases/pacira-biosciences-announces-pcrx-201-granted-regenerative-medicine-advance-therapy-rmat-designation-for-the-treatment-of-osteoarthritis-of-the-knee/